(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
In8bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast INAB's revenue for 2025 to be $1,194,730,170, with the lowest INAB revenue forecast at $1,194,730,170, and the highest INAB revenue forecast at $1,194,730,170. On average, 1 Wall Street analysts forecast INAB's revenue for 2026 to be $6,190,087,475, with the lowest INAB revenue forecast at $6,190,087,475, and the highest INAB revenue forecast at $6,190,087,475.
In 2027, INAB is forecast to generate $10,061,705,823 in revenue, with the lowest revenue forecast at $10,061,705,823 and the highest revenue forecast at $10,061,705,823.